Cargando…

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease

Detalles Bibliográficos
Autores principales:	Maas, M., Hangartner, T., Mariani, G., McHugh, K., Moore, S., Grabowski, G. A., Kaplan, P., Vellodi, A., Yee, J., Steinbach, L.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2008
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2226077/ https://www.ncbi.nlm.nih.gov/pubmed/18094966 http://dx.doi.org/10.1007/s00256-007-0425-0

Ejemplares similares

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

The Spectrum of Neurological Manifestations Associated with Gaucher Disease
por: Roshan Lal, Tamanna, et al.
Publicado: (2017)

Changing clinical manifestations of Gaucher disease in Taiwan
por: Lu, Wen-Li, et al.
Publicado: (2023)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease
por: Donald, Aimee, et al.
Publicado: (2022)

Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection
por: Maredia, Hasina, et al.
Publicado: (2023)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Chronic pain in Gaucher disease: skeletal or neuropathic origin?
por: Devigili, Grazia, et al.
Publicado: (2017)

XPF–ERCC1: Linchpin of DNA crosslink repair
por: McHugh, Peter J.
Publicado: (2020)

Recommendations on the use and reporting of race, ethnicity, and ancestry in genetic research: Experiences from the NHLBI TOPMed program
por: Khan, Alyna T., et al.
Publicado: (2022)

Stigma, biomarkers, and algorithmic bias: recommendations for precision behavioral health with artificial intelligence
por: Walsh, Colin G, et al.
Publicado: (2020)

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
por: Sims, KB, et al.
Publicado: (2008)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
por: Pogostin, Brett H., et al.
Publicado: (2021)

Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease1
por: Hughes, Derralynn, et al.
Publicado: (2007)

Recommendations for workforce development in regenerative medicine biomanufacturing
por: Green, Gary M., et al.
Publicado: (2021)

Recommendations for Measurement of Child Health Literacy: A Pragmatic Approach
por: Lane, Hannah G., et al.
Publicado: (2019)

Splenomegaly as a Primary Manifestation of Gaucher Disease in a Young Adult Woman
por: Merra, Giuseppe, et al.
Publicado: (2008)

Identification of a novel therapeutic target underlying atypical manifestation of Gaucher disease
por: Kim, Eun Na, et al.
Publicado: (2022)

Moving Canadian governmental policies beyond a focus on individual lifestyle: some insights from complexity and critical theories
por: Alvaro, C., et al.
Publicado: (2011)

Association Between Progranulin and Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Dietary recommendations for patients with dementia
por: Yerstein, Oleg, et al.
Publicado: (2020)

Ethics and informatics in the age of COVID-19: challenges and recommendations for public health organization and public policy
por: Subbian, Vignesh, et al.
Publicado: (2020)

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

Recommendations for achieving interoperable and shareable medical data in the USA
por: Szarfman, Ana, et al.
Publicado: (2022)

Challenges in developing national orthopedic health research agendas in the Netherlands: process overview and recommendations
por: RIKEN, Annabelle, et al.
Publicado: (2023)

A bright light on myosin to study skeletal muscle relaxation
por: Galli, Ricardo A., et al.
Publicado: (2020)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Lifting the mask on neurological manifestations of COVID-19
por: Pezzini, Alessandro, et al.
Publicado: (2020)

Coronavirus disease-19 and its hematological manifestations
por: Kim, Hye-Ran, et al.
Publicado: (2020)

Activation of p38 Mitogen-Activated Protein Kinase in Gaucher’s Disease
por: Kitatani, Kazuyuki, et al.
Publicado: (2015)

Recommendations for the Role of Publishers in Access to Data
por: Lin, Jennifer, et al.
Publicado: (2014)

Typhoid in Bangladesh: Challenges, efforts, and recommendations
por: Salman, Yumna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0cosodjpvn78n24un28ntmj68n